High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies
about
Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.Nonamplified FGFR1 is a growth driver in malignant pleural mesotheliomaBone marrow immunohistology of plasma cell neoplasms.Genetics of multiple myeloma: another heterogeneity level?Survival and proliferation factors of normal and malignant plasma cells.A practical approach to the detection of prognostically significant genomic aberrations in multiple myeloma.Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis.Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity.Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells.Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple MyelomaSignaling by FGFR in diseaseSignaling by FGFR3 in diseaseSignaling by FGFR3 point mutants in cancerFGFR3 mutant receptor activationt(4,14) translocations of FGFR3Dimerization of FGFR3 t(4;14) translocation mutants
P2860
Q34115051-F4801313-1CA7-4369-825D-CEBBA7C63484Q34364821-C2EAE291-2476-4004-B345-F0D70550386CQ35144166-E5B24BCC-667A-4791-A164-FEB0EE804C7EQ35197437-F4883D9D-702F-4102-9375-6F9DD7BD0E49Q35211028-FA6F73DB-B970-42AD-B16E-3B1D01AAFE5DQ35790022-59BCCF60-B9A7-4D61-AC7D-03011CDCCE29Q35810205-E336BC8B-BD0A-4ADE-98A5-D14CA9B96536Q36673626-2112D9AB-27F2-42CF-9296-7D31E1874F56Q36925154-AA8F6521-D495-42C6-A035-05C272259248Q37564773-628AED53-D524-4023-A8F8-11C0ABA21FD0Q38377097-5F6D9740-20D1-4C47-8185-F20EC4E521A1Q38974261-3A7B2461-6158-424A-B94C-B2303DDE20AEQ45314356-23354361-C7F5-462F-85C5-435C2B623C5DQ45314373-415818DF-9C2C-4F4B-97EE-F9B18865779AQ45314374-9C5E76A7-0B13-4DB7-A6DF-9B7E408F55B1Q45314375-0CC24A67-CEE4-4BCC-A705-D2C652B74C91Q45314378-4C46D91A-F1C0-42CC-A22D-5925F965B095Q50288740-A684805A-E60E-465E-BD78-F4122866C998
P2860
High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies
description
1998 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1998
@ast
im Dezember 1998 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1998/12/15)
@sk
vědecký článek publikovaný v roce 1998
@cs
wetenschappelijk artikel (gepubliceerd op 1998/12/15)
@nl
наукова стаття, опублікована в грудні 1998
@uk
مقالة علمية (نشرت في 15-12-1998)
@ar
name
High incidence of translocatio ...... with plasma cell malignancies
@ast
High incidence of translocatio ...... with plasma cell malignancies
@en
High incidence of translocatio ...... with plasma cell malignancies
@nl
type
label
High incidence of translocatio ...... with plasma cell malignancies
@ast
High incidence of translocatio ...... with plasma cell malignancies
@en
High incidence of translocatio ...... with plasma cell malignancies
@nl
prefLabel
High incidence of translocatio ...... with plasma cell malignancies
@ast
High incidence of translocatio ...... with plasma cell malignancies
@en
High incidence of translocatio ...... with plasma cell malignancies
@nl
P2093
P1433
P1476
High incidence of translocatio ...... with plasma cell malignancies
@en
P2093
A. Jaccard
C. Brigaudeau
F. Maloisel
F. Trimoreau
H. Avet-Loiseau
J. L. Harousseau
M. J. Rapp
N. Morineau
P. Talmant
P304
P407
P577
1998-12-15T00:00:00Z